Showing 1 - 2 results of 2 for search 'Mohamed M Sayed-Ahmed', query time: 0.02s Refine Results
  1. 1
    The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.

    The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial. by Riham M Karkeet, Abdelrahman N Zekri, Mohamed M Sayed-Ahmed, Ghada M Sherif, Salem E Salem, Ahmed Abdelbary, Mariam A Fouad, Sherif Y Saad

    Published 2022-01-01
    Get full text
    Article
  2. 2
    The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial

    The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial by Riham M. Karkeet, Abdelrahman N. Zekri, Mohamed M. Sayed-Ahmed, Ghada M. Sherif, Salem E. Salem, Ahmed Abdelbary, Mariam A. Fouad, Sherif Y. Saad

    Published 2022-01-01
    Get full text
    Article

Search Tools: